Acrivon Therapeutics enters the second half of 2026 with a Phase 2b registrational-intent study of ACR-368 in serous endometrial cancer that has now been re-architected around the most clinically active arm in the program, a 52% confirmed overall response rate in serous subjects announced at the European Society of Gynecological Oncology (ESGO) Annual Congress in February 2026 and elaborated at the American Association for Cancer Research (AACR) Annual Meeting in April 2026. Management has shifted the registration path to a "serous all-comer" biopsy-independent design in Arms 3 and 4, with a prespecified simultaneous interim analysis of both arms now slated for the second half of 2026, and the company has accelerated Phase 3 readiness for an ACR-368 plus PD-1 combination to mid-2026. The load-bearing event for the equity is that interim readout, because at a $1.73 share price on 42.8 million shares post the April 2026 at-the-market (ATM) raise, the company carries an enterprise value (the equity market capitalization, which is the share price multiplied by the share count, plus net debt; in Acrivon's case net cash is positive so enterprise value is below market cap) of roughly $60 million against $105 million in pro-forma cash, meaning the operating business is being valued at approximately negative $45 million, and the option value of the H2 2026 readout is the only material asset above liquidation. The single load-bearing risk is financing: cash plus investments of $97.7 million at March 31, 2026, plus $7.3 million of April 2026 ATM net proceeds, funds the operation only into the third quarter of 2027, and a Phase 3 registrational study in endometrial cancer combined with the parallel ACR-2316 WEE1/PKMYT1 program and the planned ACR-6840 IND (Investigational New Drug application, the formal request to begin human clinical trials in the United States) in the first half of 2027 implies that the next financing event is between the H2 2026 interim and the H1 2027 ACR-6840 IND. The falsifiable clock is the H2 2026 ACR-368 Arm 3 / Arm 4 interim analysis; a confirmed overall response rate (cORR) below 30% in the all-comer serous arm invalidates the biopsy-independent thesis, while a cORR above 40% with manageable hematological toxicity opens the path to a partnership or a meaningfully higher equity issuance.
The single-paragraph read for a reader with one minute: Acrivon is a clinical-stage precision oncology company with one lead asset (ACR-368, a CHK1/CHK2 inhibitor in-licensed from Eli Lilly in 2021) that has produced a 52% confirmed overall response rate in serous endometrial cancer in a pooled Phase 2b analysis, and a second clinical asset (ACR-2316, an internally discovered WEE1/PKMYT1 inhibitor) that has shown partial responses in small cell lung cancer and squamous non-small cell lung cancer, two tumor types that other WEE1 and PKMYT1 inhibitors in development have not sensitively addressed. The Q1 2026 financial print was a $19.0 million net loss on essentially flat operating expenses versus the year-ago quarter, and the company is valued below its pro-forma cash balance. The equity is a call option on a single H2 2026 event, and the price already discounts a meaningful probability of failure.